Top Research Papers on Breast Cancer

Progress against breast cancer mortality could be accelerated by mitigating racial disparities through increased access to high‐quality screening and treatment via nationwide Medicaid expansion and partnerships between community stakeholders, advocacy organizations, and health systems.

It is suggested that pathological and molecular evaluations could be used synergistically to assess risk and guide the therapeutic management of patients in field cancerization and how the use of peri‐tumoral tissues can affect research.

Postmenopausal women should also be offered postoperative bisphosphonates, and patients at high risk of breast cancer may be candidates for risk-reducing medications.

Despite the promising evidence supporting the anticancer action of gut metabolites on different cancer types, the molecular mechanisms of action of this activity are not well established, especially against breast cancer and warrant further investigation.

Translated into absolute risk of breast cancer after age 50, there is less difference in breast cancer risk across level of breast density than normally stated.

Omission of radiotherapy was associated with an increased incidence of local recurrence but had no detrimental effect on distant recurrence as the first event or overall survival among women 65 years of age or older with low-risk, hormone receptor-positive early breast cancer.

Findings of this cohort study suggest that young BC survivors without a germline pathogenic variant have a low risk of developing a SPBC in the first 10 years after diagnosis.

Survival has increased over the past few decades, with the introduction of screening mammography and improved treatments, however, progress has not been seen equally among all ethnicities/races or with all breast cancer subtypes (e.g., triple negative).

The approval of pembrolizumab in combination with chemotherapy in triple-negative breast cancer (TNBC) in the neoadjuvant and advanced settings, thereby paving the path for further research and integration of immune checkpoint inhibitors in other subtypes of breast cancer.

The crucial aspects of breast cancer survivorship, which include cancer surveillance, management of treatment side effects, implementation of a healthy lifestyle, and psychosocial support, are discussed.

This review critically evaluates existing data to develop a framework for inferring the existence of dormancy in clinical contexts of breast cancer and proposes actionable interventions that translate the wealth of knowledge gained in the laboratory to the long-term clinical management of patients at a high risk of developing recurrence.

In 310% of patients with breast cancer, the development of the disease is associated with the presence of mutations in the breast cancer gene (BRCA) 1, BRCA2, CHEK, NBS1, TP53.

A low risk of SPBC in the first 10 years after diagnosis of early BC in young women who are not germline pathogenic variant carriers is demonstrated in a prospective study of 1,302 women diagnosed with primary breast cancer from 2006-2016.

The findings confirm the prognostic value of Ki67 scores of 30% or more in women with ER-positive, HER2-negative early IBC, irrespective of interlaboratory variability and suggest that Ki67 may be useful to aid decision-making in the neoadjuvant setting.

NDRG1 expression and subcellular localisation are clinically relevant biomarkers for poor prognosis in breast cancer and breast cancer brain metastasis and establish NDRG1 as a ‘Goldilocks’ protein, where too much or too little has a negative effect on survival.

The most effective therapeutic strategy for patients with recurrent disease should be assessed evaluating biopsies obtained from metastatic sites and radiogenomics and liquid biopsy might be valuable tools to assess BC heterogeneity in a non-invasive way.

The current evidence supports the use of PBI in appropriately selected patients with early-stage breast cancer and is associated with fewer acute AEs and may be associated with less financial toxicity.

Several machine learning techniques have been proposed in this study to accurately detect and prevent breast cancer in the modern world.

The content featured in this issue focuses on the recommendations for overall management of ductal carcinoma in situ and the workup and locoregional manage- ment of early stage invasive breast cancer.

Procedure Appropriateness Category Relative Radiation Level Digital breast tomosynthesis screening Usually Appropriate ☢☢ Mammography with IV contrast Usually not Appropriate☢ US breast Usually Not Appropriate O MRI breast without and with IV Contrast Usually Not appropriating O MRI breasts without and without IV contrast abbreviated UsuallyNot Appropriate.

Across all subtypes, several novel immunotherapeutic agents are under investigation including novel ICIs, cancer vaccines, adoptive cellular therapy, and oncolytic viruses.

The structure and function of HIF-1α, its role in advancing breast cancer, and strategies to combat HIF-1α-dependent drug resistance are focused on, underlining its therapeutic potential.

The aim of this review was to depict the dynamics and kinetics of several xenobiotics involved in BC development, emphasizing the role of new omics fields related to BC exposomics, including environmental toxicogenomics, epigenomics and interactomics, metagenomics, nutrigenomics, nutriproteomics, and nutrimiRomics.

The article provides a literature review of breast carcinoma, a condition that affects women worldwide, and warns women of the disease's course, the importance of regular screenings for early detection of breast cancer, and the best treatment options.

This case highlights the clinical conundrum confronting the endoscopist in evaluating suspected linitis plastica where the imaging, endoscopic, and macroscopic histological findings between primary gastric adenocarcinoma and metastatic breast cancer can be indistinguishable.

Circulating tumor DNA is DNA released by the tumor into the bloodstream and carries many features of the original tumor and can be analyzed from a simple, non-invasive blood extraction, reviewing its potential role in early breast cancer and in metastatic breast cancer.

High certainty evidence that mammography screening reduces BC mortality risk would support policymakers formulating strong recommendations in other age groups, where the net balance of effects is less clear, conditional recommendations will be more likely, together with shared decision-making.

This review focused on Nrf2 modulators and their roles in sensitizing breast cancer cells to chemo/radiotherapy agents and its inhibitory/stimulatory position and targeting.

A review of studies examining the heterogeneity of CAFs in breast cancer and expression patterns of CAF markers in different subtypes of breast cancer hopes that summarizing CAF‐related studies from a historical perspective will help to accelerate the development ofCAF‐targeted therapeutic strategies for breast cancer.

The presence of cell-free tumor DNA was reported in breast milk from patients with breast cancer, and its use as a screening method surpassed plasma liquid biopsy in terms of detecting and molecularly profiling early-stage tumors, even prior to diagnosis.

Despite the COVID 19 pandemic and mostly virtual congresses, innovation in the treatment of breast cancer patients continues at an unabated pace, and new compounds such as oral selective estrogen receptor destabilisers (SERDs) are entering clinical development and completing the first phase III trials.

Four cases of recurrence more than 10 years after the initial diagnosis are presented, which were all estrogen receptor (ER)-positive, and one was also human epidermal growth factor receptor 2-positive.

First primary ER status in BRCA1/2 strongly predicts the second tumour will be the same ER status even if unusual for PVs in that gene, and high rates of HER2+ were associated with CHEK2 PVs, and women ≤30 years wereassociated with TP53 PVs.

A predictive model for the risk of developing CBC is built based on a large data cohort to help clinicians identify patients at high risk, which can then help them plan individualized surveillance and treatment.

The histologic and molecular classifications of TNBC, the genomic alterations these different tumor types harbor, and the potential impact of these alterations on the pathogenesis of these tumors are discussed.

In this study, deleterious variants in breast cancer susceptibility genes were associated with differential rates of ER-specific CBC subtypes, providing further evidence of distinct etiologies of CBC subtypes.

The goal of the current review is to ascertain whether breast cancer treatment and evaluation methods used on female patients are suitable for this type of cancer.

Among women who were at least 55 years of age and had T1N0, grade 1 or 2, luminal A breast cancer that were treated with breast-conserving surgery and endocrine therapy alone, the incidence of local recurrence at 5 years was low with the omission of radiotherapy, and the upper boundary of the two-sided 90% confidence interval for the cumulative incidence at5 years was less than 5.

Adding BMI and extended family history to the BCSC model improved discrimination and the true positive rate and the inclusion of BMI was associated with the largest improvement in estimated risk for individual women.

The issue is of greater significance in older rather than younger women due to competing causes of death, and the actual amount of overdetection is likely to be much lower than the estimate used by the Canadian Task Force on Preventive Health Care.

The objective of this project is to train machine learning models to predict whether a breast cancer cell is Benign or Malignant, and to make a performance comparison between different machine learning algorithms in order to assess the correctness in classifying data with respect to efficiency and effectiveness.

What CRISPR consists of and its applications in breast cancer while focusing on TNBC research are explained, the search for novel genes involved in tumour progression, sensitivity to drugs and immunotherapy response, tumour fitness, diagnosis, and treatment, and the limitations that CRISpr technology is subject to are highlighted.

This narrative review summarizes epidemiological studies on breast cancer and prostate cancer with an overview of their global incidence distribution to investigate the relationship between these diseases and diet. The biological properties, mechanisms of action, and available data supporting the potential role of isoflavones in the prevention of breast cancer and prostate cancer are discussed. Studies evaluating the effects of isoflavones in tissue cultures of normal and malignant breast and prostate cells, as well as the current body of research regarding the effects of isoflavones attained ...

A comprehensive review of the pathology, epidemiology, clinical presentation, referral pathways and management of breast cancer in the UK and how to conduct a thorough clinical breast examination is provided.

La reconstrucción inmediata es la opción preferible siempre that sea posible, ya que ofrece buenos resultados estéticos y evita mayor número of intervenciones quirúrgicas.

This review will summarize the distinct biological and molecular features of invasive lobular carcinoma, focusing on the diagnostic challenges faced and the subsequent surgical and medical management strategies.

Progress against breast cancer could be accelerated by mitigating racial, ethnic, and social disparities through improved clinical trial representation and access to high-quality screening and treatment.

Insight is provided into better understanding the mutational landscape of BCSCs and exploring potential molecular signaling pathways targetingBCSCs to overcome chemoresistance and prevent metastasis in TNBC, ultimately to improve the overall survival of patients with this devastating disease.

This review provides a comprehensive summary of the available classification strategies for TNBC, evaluating the overlap between the molecular, immunohistochemical, and clinical characteristics between these approaches and a perspective about the increasing applications of artificial intelligence to identify definitive and clinically relevant TNBC subtypes.

Four discrete molecular subtypes of BC are recognized on the basis of an ER-PR test and HER2 status, which informs a specific treatment regimen and is predictive of disease recurrence and mortality rate.